Support Groundbreaking Research

When you fund our research, the results won’t just be seen in the lab. They’ll be seen in life-changing breakthroughs for thousands of people with Parkinson’s.

Together, we can deliver an effective treatment for hallucinations

Parkinson’s can bring about changes in the brain that cause hallucinations (sensing something that does not exist). Or hallucinations can be a side effect of Parkinson’s medication.

Professor Suzanne Reeves has found a drug, ondansetron, that may have potential to reduce hallucinations.

It’s already used in the NHS to stop people feeling sick after cancer treatments. If we can prove it’s safe and effective in treating hallucinations, we could have the ‘rubber stamp’ on a new Parkinson’s treatment in just a few years. 

We’re ready to fund a nationwide clinical trial. 216 people with Parkinson’s across the UK will take part. 

Slice title
Will you donate today to help fund this groundbreaking trial?

Slice text

Together, we can take steps towards a new treatment

  • Paypal accepted
  • Mastercard accepted
  • Visa accepted
  • American Express accepted

Why is treating hallucinations important?

3 out of 4 people with Parkinson’s will experience hallucinations at some point. It can be extremely unsettling but currently there’s no treatment approved in the UK.

It’s vital we find better treatments. Many people with Parkinson’s found that their symptoms worsened during the pandemic.

If successful, this trial could see this drug, which is already used in the NHS, quickly repurposed to become an available treatment in Parkinson’s.

And not only that. Professor Reeves believes ondansetron has the potential to treat other Parkinson’s symptoms such as tremors, anxiety, delusions and sleep and memory problems

Watch the video below to find out more. 

Bringing life-changing treatments closer

The Trial of Ondansetron as a Parkinson’s Hallucination Treatment (TOPHAT) will compare the effects of taking ondansetron with the effects of taking a placebo, or dummy pill.

Participants will take either ondansetron or the placebo for 12 weeks. They will be assessed before, during and after the 12 week treatment.

A focus group of people with Parkinson’s has helped Professor Suzanne Reeves design this phase 2 trial. Over 30 hospitals across the UK have either expressed an interest or are already signed up to take part. 

We’re aiming to raise £144,072 to assess, monitor and collect data from each of the 216 participants in the TOPHAT trial.

Together, we can deliver a treatment that could make life better for thousands of people with Parkinson’s. Soon.

What's promising about this research?

We already know ondansetron is safe for people to take. By testing the drug in people with Parkinson’s who experience hallucinations, we can discover if it is both safe and effective as a treatment.

This is a big, nationwide trial with 216 participants. That’s how confident we are that ondansetron could be an effective treatment for hallucinations.

What’s next? 

If this phase 2 trial proves ondansetron is effective, the next step will be to partner with a pharmaceutical company for larger-scale clinical trials. 

With your help, within a few years, we could see clinicians repurposing ondansetron to treat people with Parkinson’s hallucinations throughout the UK.

Together, we can develop better treatments for everyone affected by Parkinson's.

Can you donate now to support this clinical trial?